1.
|
|
2.
|
15 p, 1.2 MB |
Proteomic Analysis in Seminal Plasma of Fertile Donors and Infertile Patients with Sperm DNA Fragmentation
/
Fernandez-Encinas, Alba (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, Fisiologia i Immunologia) ;
García-Peiró, Agustín (Centro de Infertilidad Masculina y Análisis de Barcelona (CIMAB)) ;
Del Rey Azpiri, Javier (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, Fisiologia i Immunologia) ;
Ribas-Maynou, Jordi (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, Fisiologia i Immunologia) ;
Abad, Carlos (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Amengual, Maria José (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Prada, Elena (Hospital Universitari Mutua de Terrassa. Servei de Ginecologia) ;
Navarro i Ferreté, Joaquima (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, Fisiologia i Immunologia) ;
Benet i Català, Jordi (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, Fisiologia i Immunologia)
Seminal plasma proteomics studies could represent a new approach for the determination of molecular elements driving male infertility, resulting in a better male infertility characterization. The aim of this study is to investigate proteomic differences in seminal plasma samples from fertile and infertile individuals. [...]
2020 - 10.3390/ijms21145046
International journal of molecular sciences, Vol. 21, Núm. 14 (July 2020) , art. 5046
|
|
3.
|
10 p, 595.1 KB |
Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma
/
Wick, Antje (Heidelberg University Medical Center. Clinical Cooperation Unit Neuro-oncology, German Cancer Research Center) ;
Desjardins, Annick (Duke University. The Preston Robert Tisch Brain Tumor Center at Duke) ;
Suarez, Cristina (VHIO) ;
Forsyth, Peter (H. Lee Moffitt Cancer Center and Research Institute) ;
Gueorguieva, Ivelina (Eli Lilly and Company) ;
Burkholder, Tiana (Eli Lilly and Company) ;
Cleverly, Ann Louise (Eli Lilly and Company) ;
Estrem, Shawn T. (Eli Lilly and Company) ;
Wang, Shuaicheng (BioStat Solutions, Inc, Frederick, MD USA) ;
Lahn, Michael M. (Eli Lilly and Company) ;
Guba, Susan C. (Eli Lilly and Company) ;
Capper, David (Department of Neuropathology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany) ;
Rodon Ahnert, Jordi (VHIO) ;
Universitat Autònoma de Barcelona
The online version of this article (10. 1007/s10637-020-00910-9) contains supplementary material, which is available to authorized users.
2020 - 10.1007/s10637-020-00910-9
Investigational New Drugs, Vol. 38 (march 2020) , p. 1570-1579
|
|
4.
|
23 p, 4.1 MB |
Personalized cancer therapy prioritization based on driver alteration co-occurrence patterns
/
Mateo, Lidia (The Barcelona Institute of Science and Technology. Joint IRB-BSC-CRG Program in Computational Biology, Institute for Research in Biomedicine (IRB Barcelona)) ;
Duran-Frigola, Miquel (The Barcelona Institute of Science and Technology. Joint IRB-BSC-CRG Program in Computational Biology, Institute for Research in Biomedicine (IRB Barcelona)) ;
Gris-Oliver, Albert (VHIO) ;
Palafox, Marta (VHIO) ;
Scaltriti, Maurizio (MSKCC. Department of Pathology) ;
Razavi, Pedram (MSKCC and Weill-Cornell Medical College. Breast Medicine Service, Department of Medicine) ;
Chandarlapaty, Sarat (MSKCC and Weill-Cornell Medical College. Breast Medicine Service, Department of Medicine) ;
Arribas, Joaquin (VHIO) ;
Bellet, Meritxell (VHIO) ;
Serra, Violeta (VHIO) ;
Aloy, Patrick (Institució Catalana de Recerca i Estudis Avançats (ICREA))
Identification of actionable genomic vulnerabilities is key to precision oncology. Utilizing a large-scale drug screening in patient-derived xenografts, we uncover driver gene alteration connections, derive driver co-occurrence (DCO) networks, and relate these to drug sensitivity. [...]
2020 - 10.1186/s13073-020-00774-x
Genome Medicine, Vol. 12 (september 2020)
|
|
5.
|
12 p, 774.2 KB |
Kappa free light chains is a valid tool in the diagnostics of MS : A large multicenter study
/
Leurs, CE ;
Twaalfhoven, HAM ;
Lissenberg-Witte, BI ;
van Pesch, V ;
Dujmovic, I ;
Drulovic, J ;
Castellazzi, M ;
Bellini, T ;
Pugliatti, M ;
Kuhle, J ;
Villar, LM ;
Alvarez-Cermeño, JC ;
Alvarez-Lafuente, R ;
Hegen, H ;
Deisenhammer, F ;
Walchhofer, LM ;
Thouvenot, E ;
Comabella, M (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Montalban, X (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Vécsei, L ;
Rajda, C ;
Galimberti, D ;
Scarpini, E ;
Altintas, A ;
Rejdak, K ;
Frederiksen, JL ;
Pihl-Jensen, G ;
Jensen, PEH ;
Khalil, M ;
Voortman, MM ;
Fazekas, F ;
Saiz, Albert ;
La Puma, D ;
Vercammen, M ;
Vanopdenbosch, L ;
Uitdehaag, BMJ ;
Killestein, J ;
Bridel, C ;
Teunissen, C ;
Universitat Autònoma de Barcelona
To validate kappa free light chain (KFLC) and lambda free light chain (LFLC) indices as a diagnostic biomarker in multiple sclerosis (MS). We performed a multicenter study including 745 patients from 18 centers (219 controls and 526 clinically isolated syndrome (CIS)/MS patients) with a known oligoclonal IgG band (OCB) status. [...]
2019 - 10.1177/1352458519845844
Multiple sclerosis, Vol. 26 (may 2019) , p. 912-923
|
|
6.
|
9 p, 2.2 MB |
Obesity impacts brain metabolism and structure independently of amyloid and tau pathology in healthy elderly
/
Pegueroles, Jordi (Institut d'Investigació Biomèdica Sant Pau) ;
Pané, Adriana (Hospital Clínic i Provincial de Barcelona) ;
Vilaplana, Eduard (Institut d'Investigació Biomèdica Sant Pau) ;
Montal, Víctor (Institut d'Investigació Biomèdica Sant Pau) ;
Bejanin, Alexandre (Institut d'Investigació Biomèdica Sant Pau) ;
Videla, Laura (Institut d'Investigació Biomèdica Sant Pau) ;
Carmona Iragui, María (Institut d'Investigació Biomèdica Sant Pau) ;
Barroeta, Isabel (Institut d'Investigació Biomèdica Sant Pau) ;
Ibarzabal, Ainitze (Hospital Clínic i Provincial de Barcelona) ;
Casajoana, Anna (Hospital Universitari de Bellvitge) ;
Alcolea, Daniel (Institut d'Investigació Biomèdica Sant Pau) ;
Valldeneu, Silvia (Institut d'Investigació Biomèdica Sant Pau) ;
Altuna, Miren (Institut d'Investigació Biomèdica Sant Pau) ;
de Hollanda, Ana (IDIBAPS) ;
Vidal, Josep (IDIBAPS) ;
Ortega, Emilio (IDIBAPS) ;
Osorio, Ricardo (New York University School of Medicine) ;
Convit, Antonio (New York University School of Medicine) ;
Blesa, Rafael (Institut d'Investigació Biomèdica Sant Pau) ;
Lleó, Alberto (Institut d'Investigació Biomèdica Sant Pau) ;
Fortea, Juan (Institut d'Investigació Biomèdica Sant Pau) ;
Jiménez, Amanda (IDIBAPS) ;
Universitat Autònoma de Barcelona
Midlife obesity is a risk factor for dementia. We investigated the impact of obesity on brain structure, metabolism, and cerebrospinal fluid (CSF) core Alzheimer's disease (AD) biomarkers in healthy elderly. [...]
2020 - 10.1002/dad2.12052
Alzheimer's & dementia, Vol. 12 (july 2020)
|
|
7.
|
9 p, 631.3 KB |
The ANTENATAL multicentre study to predict postnatal renal outcome in fetuses with posterior urethral valves : objectives and design
/
Buffin-Meyer, Bénédicte (Université Toulouse III Paul-Sabatier) ;
Klein, Julie (Université Toulouse III Paul-Sabatier) ;
van der Zanden, Loes F M (Department for Health Evidence, Radboud Institute for Health Sciences, Radboud University Medical Center) ;
Levtchenko, Elena (Department of Development & Regeneration) ;
Moulos, Panogiotis (HybridStat Predictive Analytics) ;
Lounis, Nadia (Unité de Recherche Clinique Pédiatrique, Module Plurithématique Pédiatrique du Centre D'Investigation Clinique Toulouse 1436) ;
Conte-Auriol, Françoise (Unité de Recherche Clinique Pédiatrique, Module Plurithématique Pédiatrique du Centre D'Investigation Clinique Toulouse 1436) ;
Hindryckx, An (Department of Obstetrics and Gynaecology, University Hospitals Leuven) ;
Wühl, Elke (Division of Pediatric Nephrology, Center for Pediatrics and Adolescent Medicine, University Hospital Heidelberg) ;
Persico, Nicola (Sergio Bonelli Centre for the Prevention of Renal Failure from Fetal to Pediatric Age) ;
Oepkes, Dick (Department of Prenatal Diagnosis and Therapy, Leiden University Medical Center) ;
Schreuder, Michiel F (Department of Pediatric Nephrology, Radboudumc Amalia Children's Hospital, Radboud Institute for Molecular Life Sciences) ;
Tkaczyk, Marcin (Department of Pediatrics, Immunology and Nephrology, Polish Mother's Memorial Hospital Research Institute) ;
Ariceta, Gema (Universitat Autónoma de Barcelona. Departament de Pediatria, Obstetrícia i Ginecologia i de Medicina Preventiva i Salut Pública) ;
Fossum, Magdalena (Section of Pediatric Urology, Department of Highly Specialized Pediatric Surgery and Pediatric Medicine, Karolinska University Hospital and Department of Women's and Children's Health, Karolinska Institutet) ;
Parvex, Paloma (Pediatric Nephrology, Unité Romande de Néphrologie Pédiatrique, Hôpitaux Universitaire Genève (HUG)) ;
Feitz, Wout (For ERN eUROGEN, Department of Urology, Radboudumc Amalia Children's Hospital, Radboud University Medical Center) ;
Olsen, Henning (For ERN eUROGEN, Paediatric Urology, Department of Urology, Aarhus University Hospital & Aarhus University) ;
Montini, Giovanni (For ERN ERKNet, Pediatric Nephrology-Centro Sergio Bonelli for the Prevention and Treatment of Urinary Tract Malformations) ;
Decramer, Stéphane (Centre De Référence des Maladies Rénales Rares du Sud-Ouest (SORARE)) ;
Schanstra, Joost P (Université Toulouse III Paul-Sabatier)
Posterior urethral valves (PUV) account for 17% of paediatric end-stage renal disease. A major issue in the management of PUV is prenatal prediction of postnatal renal function. Fetal ultrasound and fetal urine biochemistry are currently employed for this prediction, but clearly lack precision. [...]
2019 - 10.1093/ckj/sfz107
Clinical Kidney Journal, Vol. 13 (september 2019) , p. 371-379
|
|
8.
|
9 p, 763.7 KB |
The combined effect of amyloid-β and tau biomarkers on brain atrophy in dementia with Lewy bodies
/
Abdelnour, Carla (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Ferreira, Daniel (Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden) ;
Oppedal, Ketil (Department of Electrical Engineering and Computer Science, University of Stavanger, Stavanger, Norway) ;
Cavallin, Lena (Department of Neuroscience, Karolinska Institutet and Department of Radiology Karolinska University Hospital, Stockholm, Sweden) ;
Bousiges, Olivier (Hôpitaux Universitaire de Strasbourg, Laboratoire de Biochimie et Biologie Moléculaire, et CNRS, Laboratoire de Neurosciences Cognitives et Adaptatives (LNCA), UMR7364, Strasbourg, France) ;
Wahlund, Lars Olof (Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden) ;
Hort, Jakub (International Clinical Research Centre, Brno, Czech Republic) ;
Nedelska, Zuzana (International Clinical Research Centre, Brno, Czech Republic) ;
Padovani, Alessandro (Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy) ;
Pilotto, Andrea (Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy) ;
Bonanni, Laura (Department of Neuroscience Imaging and Clinical Sciences and CESI, University G d'Annunzio of Chieti-Pescara, Chieti, Italy) ;
Kramberger, Milica G. (Department of Neurology, University Medical Centre Ljubljana, Medical faculty, University of Ljubljana, Ljubljana, Slovenia) ;
Boada, Mercè (Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, Centro de Investigación en Red-Enfermedades Neurodegenerativas (CIBERNED), Barcelona, Spain) ;
Westman, Eric (Department of Neuroimaging, Centre for Neuroimaging Sciences, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK) ;
Pagonabarraga, Javier (Institut d'Investigació Biomèdica Sant Pau) ;
Kulisevsky, Jaime (Institut d'Investigació Biomèdica Sant Pau) ;
Blanc, Frédéric (Hôpitaux Universitaire de Strasbourg, CMRR (Centre Mémoire de Ressource et de Recherche), Hôpital de jour, pôle de Gériatrie, et CNRS, laboratoire ICube UMR 7357 et FMTS (Fédération de MédecineTranslationnelle de Strasbourg), équipe IMIS/Neurocrypto, Strasbourg, France) ;
Aarsland, Dag (Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK)
Alzheimer's disease (AD)-related pathology is frequently found in patients with dementia with Lewy bodies (DLB). However, it is unknown how amyloid-β and tau-related pathologies influence neurodegeneration in DLB. [...]
2020 - 10.1016/j.nicl.2020.102333
NeuroImage, Vol. 27 (july 2020)
|
|
9.
|
12 p, 2.1 MB |
Challenges associated with biomarker-based classification systems for Alzheimer's disease
/
Illán-Gala, Ignacio (Institut d'Investigació Biomèdica Sant Pau) ;
Pegueroles, Jordi (Institut d'Investigació Biomèdica Sant Pau) ;
Montal, Victor (Institut d'Investigació Biomèdica Sant Pau) ;
Vilaplana, Eduard (Institut d'Investigació Biomèdica Sant Pau) ;
Carmona Iragui, María (Institut d'Investigació Biomèdica Sant Pau) ;
Alcolea, Daniel (Institut d'Investigació Biomèdica Sant Pau) ;
Dickerson, Bradford C. (Massachusetts Alzheimer's Disease Research Center, Boston, MA, USA) ;
Sánchez-Valle, Raquel (Alzheimer's Disease and Other Cognitive Disorders Unit, Department of Neurology, Hospital Clínic, Institut d'Investigació Biomèdica August Pi i Sunyer, Barcelona, Spain) ;
de Leon, Mony J. (Centre for Brain Health, Department of Psychiatry, New York University School of Medicine, New York, NY, USA) ;
Blesa, Rafael (Institut d'Investigació Biomèdica Sant Pau) ;
Lleó, Alberto (Institut d'Investigació Biomèdica Sant Pau) ;
Fortea, Juan (Institut d'Investigació Biomèdica Sant Pau) ;
Universitat Autònoma de Barcelona
We aimed to evaluate the consistency of the A/T/N classification system. We included healthy controls, mild cognitive impairment, and dementia patients from Alzheimer's disease Neuroimaging Initiative. [...]
2018 - 10.1016/j.dadm.2018.03.004
Alzheimer's & dementia, Vol. 10 (april 2018) , p. 346-357
|
|
10.
|
|